HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Lawrence H. Cohn Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farivar, R. S. Articles by Cohn, L. H. Search for Related Content PubMed PubMed Citation Articles by Farivar, R. S. Articles by Cohn, L. H. Related Collections Valve disease

J Thorac Cardiovasc Surg 2003;126:969-975
© 2003 The American Association for Thoracic Surgery

Surgery for acquired cardiovascular disease

Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation

^a Division of Cardiac Surgery, Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Mass, USA

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

Received for publication March 13, 2003; revisions received April 14, 2003; accepted for publication April 21, 2003.

^* Address for reprints: Lawrence H. Cohn, MD, Division of Cardiac Surgery, Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115, USA
lcohn{at}partners.org

OBJECTIVE: There are pathophysiologic similarities between calcification and atherosclerosis. We wished to determine whether risk factors for atherosclerosis were linked to bioprosthetic valve calcification and dysfunction.

METHODS: We performed a retrospective cohort study on 144 patients at a single institution who had bioprosthetic aortic or mitral valves removed, serum cholesterol levels recorded, and valve calcification assessed on the basis of hematoxylin and eosin staining and radiography of the valve. We also performed case-control analysis of a group of 66 patients whose tissue valves were explanted and compared them with an age- and position-matched group of 66 patients with similar duration of implantation. We also compared mean serum cholesterol levels.

RESULTS: In the retrospective cohort study cholesterol (P = .035), younger age at implantation (P = .014), and coronary artery disease (P = .017) were linked to calcification of the valve by means of univariate analysis. In stepwise multiple regression analysis only the mean serum cholesterol level was linked to calcification (P = .02). Sex, hypertension, smoking, diabetes, and implant position were not linked to calcification. In the case-control analysis the mean serum cholesterol level of the explanted valve group was significantly higher (189 vs 163 mg/dL, P < .0001) than that of the group whose valves did not require explantation. For those whose serum cholesterol levels were greater than 200 mg/dL, the odds ratio was 3.9 (95% confidence interval, 1.7-8.9) for valve explantation.

CONCLUSIONS: Increased serum cholesterol level may be a risk factor for bioprosthetic valve calcification requiring explantation.

This article has been cited by other articles:

				M. Briand, P. Pibarot, J.-P. Despres, P. Voisine, J. G. Dumesnil, F. Dagenais, and P. Mathieu Metabolic Syndrome Is Associated With Faster Degeneration of Bioprosthetic Valves Circulation, July 4, 2006; 114(1_suppl): I-512 - I-517. [Abstract] [Full Text] [PDF]

				Should all patients receive statins before cardiac surgery: are more data necessary? J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 520 - 522.

				F. J. Schoen and R. J. Levy Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention Ann. Thorac. Surg., March 1, 2005; 79(3): 1072 - 1080. [Abstract] [Full Text] [PDF]